UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 76

Sortiert nach

Tyrosine Kinase Receptor Landscape in Lung Cancer: Therapeutical Implications

Disease markers, 2016-01, Vol.2016, p.9214056-14

2016

Volltextzugriff (PDF)

Corrigendum to “Tyrosine Kinase Receptor Landscape in Lung Cancer: Therapeutical Implications”

Disease markers, 2018, Vol.2018, p.3714684-1

2018

Volltextzugriff (PDF)

222 Platelet derived growth factor receptor (PDGFRβ) as a predictive biomarker of response to antiangiogenics in renal cell cancer (RCC) cell lines

European journal of cancer (1990), 2015-09, Vol.51, p.S34-S34

2015

Volltextzugriff (PDF)

3038 IL-, Novel protein diagnostic biomarker of lung adenocarcinoma in bronchoalveolar lavage

European journal of cancer (1990), 2015-09, Vol.51, p.S609-S609

2015

Volltextzugriff (PDF)

3040 Differential diagnostic profiles of lung cancer and chronic obstructive pulmonary disease using cytokine-based assays

European journal of cancer (1990), 2015-09, Vol.51, p.S609-S609

2015

Volltextzugriff (PDF)

EP16.03-030 AKT Inhibition as a Therapeutic Strategy to Constrain Histological Transdifferentiation in EGFR-mutant Lung Adenocarcinoma

Journal of thoracic oncology, 2022-09, Vol.17 (9), p.S602

2022

Volltextzugriff (PDF)

OA19.03 Exportin 1 Inhibition Constraints Lineage Plasticity and Histological Transformation through Downregulation of SOX2

Journal of thoracic oncology, 2023-11, Vol.18 (11), p.S87-S88

2023

Volltextzugriff (PDF)

MA04.08 Identifying Early and Late Hallmarks of Plasticity in Neuroendocrine Transformation of Lung Cancer at Single-Cell Level

Journal of thoracic oncology, 2023-11, Vol.18 (11), p.S111-S112

2023

Volltextzugriff (PDF)

MA16.03 CRISPR Screen Reveals XPO1 as a Therapeutic Target Strongly Sensitizing to First and Second Line Therapy in Small Cell Lung Cancer

Journal of thoracic oncology, 2021-10, Vol.16 (10), p.S938-S938

2021

Volltextzugriff (PDF)

MA11.06 Multi-Omic Characterization of Lung Tumors Implicates AKT and MYC Signaling in Adenocarcinoma to Squamous Cell Transdifferentiation

Journal of thoracic oncology, 2021-10, Vol.16 (10), p.S919-S919

2021

Volltextzugriff (PDF)

OA07.01 Signatures of Plasticity and Immunosuppression in a Single-Cell Atlas of Human Small Cell Lung Cancer

Journal of thoracic oncology, 2021-10, Vol.16 (10), p.S858-S858

2021

Volltextzugriff (PDF)

FGFR4 exerts differential roles in tumorigenesis through a mechanism of cooperation

Annals of oncology, 2016-10, Vol.27, p.vi540-vi540

2016

Volltextzugriff (PDF)

2233MO CDC7 inhibition constrains lineage plasticity and prevents resistance and neuroendocrine transformation in the lung and prostate

Annals of oncology, 2023-10, Vol.34, p.S1150-S1150

2023

Volltextzugriff (PDF)

22P Exploring exportin-1 as a therapeutic vulnerability in lung squamous cell carcinoma

ESMO open, 2023-10, Vol.8 (1), p.101668, Article 101668

2023

Volltextzugriff (PDF)

2MO XPO1 inhibition strongly sensitizes to first-line and second-line therapy in small cell lung cancer

Annals of oncology, 2021-10, Vol.32, p.S1345

2021

Volltextzugriff (PDF)

1MO Multi-omic characterization of lung tumors identify AKT and EZH2 as potential therapeutic targets in adenocarcinoma-to-squamous transdifferentiation

Annals of oncology, 2021-10, Vol.32, p.S1345

2021

Volltextzugriff (PDF)

1800O Multi-omic characterization of lung tumors implicates AKT and MYC signaling in adenocarcinoma to squamous cell transdifferentiation

Annals of oncology, 2021-09, Vol.32, p.S1226-S1226

2021

Volltextzugriff (PDF)

228P SMARCA4 inactivation drives aggressiveness in STK11/KEAP1 co-mutant lung adenocarcinomas through the induction of TGFβ signaling

ESMO open, 2024-03, Vol.9, p.102878, Article 102878

2024

Volltextzugriff (PDF)

Lineage plasticity in cancer: a shared pathway of therapeutic resistance

Nature reviews. Clinical oncology, 2020-06, Vol.17 (6), p.360-371

2020

Volltextzugriff (PDF)

Neuroendocrine neoplasms of the lung and gastrointestinal system: convergent biology and a path to better therapies

Nature reviews. Clinical oncology, 2023-01, Vol.20 (1), p.16-32

2023

Volltextzugriff (PDF)

Concurrent Mutations in STK11 and KEAP1 Promote Ferroptosis Protection and SCD1 Dependence in Lung Cancer

Cell reports (Cambridge), 2020-12, Vol.33 (9), p.108444-108444, Article 108444

2020

Volltextzugriff (PDF)

Epigenetics of lung cancer: a translational perspective

Cellular oncology (Dordrecht), 2019-12, Vol.42 (6), p.739-756

2019

Volltextzugriff (PDF)

WEE1 inhibition enhances the antitumor immune response to PD-L1 blockade by the concomitant activation of STING and STAT1 pathways in SCLC

Cell reports (Cambridge), 2022-05, Vol.39 (7), p.110814-110814, Article 110814

2022

Volltextzugriff (PDF)

Concurrent RB1 and TP53 Alterations Define a Subset of EGFR-Mutant Lung Cancers at risk for Histologic Transformation and Inferior Clinical Outcomes

Journal of thoracic oncology, 2019-10, Vol.14 (10), p.1784-1793

2019

Volltextzugriff (PDF)

1 – 25 von 76

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(70)
Mit Volltextzugriff
(70)

Publikationsform

Artikel
(76)

Sprache

Englisch
(76)
Japanisch
(7)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Tyrosine Kinase Receptor Landscape in Lung Cancer: Therapeutical Implications

Corrigendum to “Tyrosine Kinase Receptor Landscape in Lung Cancer: Therapeutical Implications”

222 Platelet derived growth factor receptor (PDGFRβ) as a predictive biomarker of response to antiangiogenics in renal cell cancer (RCC) cell lines

3038 IL-, Novel protein diagnostic biomarker of lung adenocarcinoma in bronchoalveolar lavage

3040 Differential diagnostic profiles of lung cancer and chronic obstructive pulmonary disease using cytokine-based assays

EP16.03-030 AKT Inhibition as a Therapeutic Strategy to Constrain Histological Transdifferentiation in EGFR-mutant Lung Adenocarcinoma

OA19.03 Exportin 1 Inhibition Constraints Lineage Plasticity and Histological Transformation through Downregulation of SOX2

MA04.08 Identifying Early and Late Hallmarks of Plasticity in Neuroendocrine Transformation of Lung Cancer at Single-Cell Level

MA16.03 CRISPR Screen Reveals XPO1 as a Therapeutic Target Strongly Sensitizing to First and Second Line Therapy in Small Cell Lung Cancer

MA11.06 Multi-Omic Characterization of Lung Tumors Implicates AKT and MYC Signaling in Adenocarcinoma to Squamous Cell Transdifferentiation

OA07.01 Signatures of Plasticity and Immunosuppression in a Single-Cell Atlas of Human Small Cell Lung Cancer

FGFR4 exerts differential roles in tumorigenesis through a mechanism of cooperation

2233MO CDC7 inhibition constrains lineage plasticity and prevents resistance and neuroendocrine transformation in the lung and prostate

22P Exploring exportin-1 as a therapeutic vulnerability in lung squamous cell carcinoma

2MO XPO1 inhibition strongly sensitizes to first-line and second-line therapy in small cell lung cancer

1MO Multi-omic characterization of lung tumors identify AKT and EZH2 as potential therapeutic targets in adenocarcinoma-to-squamous transdifferentiation

1800O Multi-omic characterization of lung tumors implicates AKT and MYC signaling in adenocarcinoma to squamous cell transdifferentiation

228P SMARCA4 inactivation drives aggressiveness in STK11/KEAP1 co-mutant lung adenocarcinomas through the induction of TGFβ signaling

Lineage plasticity in cancer: a shared pathway of therapeutic resistance

Signatures of plasticity, metastasis, and immunosuppression in an atlas of human small cell lung cancer

Neuroendocrine neoplasms of the lung and gastrointestinal system: convergent biology and a path to better therapies

Concurrent Mutations in STK11 and KEAP1 Promote Ferroptosis Protection and SCD1 Dependence in Lung Cancer

Epigenetics of lung cancer: a translational perspective

WEE1 inhibition enhances the antitumor immune response to PD-L1 blockade by the concomitant activation of STING and STAT1 pathways in SCLC

Concurrent RB1 and TP53 Alterations Define a Subset of EGFR-Mutant Lung Cancers at risk for Histologic Transformation and Inferior Clinical Outcomes

Suchergebnisse filtern